Oral candidiasis in human immunodeficiency virus-infected patients under highly active antiretroviral therapy
- Resource Type
- Authors
- Supriya Kheur; Madhura Shekatkar; A. Thirumal Raj; Kamran Habib Awan; Samar Khan; Shankargouda Patil; Archana A. Gupta; Ami Desai; William B. Carroll; Aavishi Arora
- Source
- Disease-a-month : DM. 67(9)
- Subject
- medicine.medical_specialty
Acquired Immunodeficiency Syndrome
Mouth
AIDS-Related Opportunistic Infections
business.industry
Anti-HIV Agents
Incidence (epidemiology)
Human immunodeficiency virus (HIV)
HIV
HIV Infections
030206 dentistry
General Medicine
medicine.disease_cause
Antiretroviral therapy
Treatment failure
03 medical and health sciences
0302 clinical medicine
Candidiasis, Oral
Internal medicine
Antiretroviral Therapy, Highly Active
medicine
Humans
030212 general & internal medicine
business
- Language
- ISSN
- 1557-8194
Human immunodeficiency virus has plagued mankind since the 1980’s when the first case was documented. Human immunodeficiency virus-induced immunocompromised state can lead to several systemic and local manifestations, which often culminates in mortality. Oral candidiasis was one of the most prevalent opportunistic infections noted in human immunodeficiency virus-infected patients. The advent of highly active antiretroviral therapy has led to a significant reduction in both the mortality and the morbidity of infected patients. The combined antiretroviral therapy has also led to a decrease in the incidence of opportunistic infections including oral candidiasis. Thus, the presence of well-established oral candidiasis in human immunodeficiency virus-infected patients under highly active antiretroviral therapy could be considered as an indicator of potential treatment failure. The present manuscript aims to review the published literature assessing the effect of highly active antiretroviral therapy on the incidence of oral candidiasis in human immunodeficiency virus-infected patients.